PepGen (PEPG) Skyrockets 121% on Stellar Experimental Treatment Trial Results

Core Viewpoint - PepGen Inc. (NASDAQ:PEPG) experienced a significant stock price increase of 121.05% following positive results from its clinical trial for an experimental drug aimed at treating myotonic dystrophy type 1 (DM1) [1][3]. Group 1: Clinical Trial Results - The clinical trial demonstrated a 53.7% correction in the key genetic error associated with DM1 in patients administered 15 mg/kg of the drug candidate PGN-EDODM1, surpassing previous reports of splicing correction in DM1 patients [2]. - The study achieved all key objectives, including unprecedented splicing correction after a single dose of PGN-EDODM1 at 15 mg/kg, as stated by the EVP for research and development [3]. Group 2: Financial Actions - Following the positive trial results, PepGen initiated a $100 million public offering, which includes the sale of 31.25 million shares priced at $3.20 each [4]. - The proceeds from the public offering will be allocated to ongoing research and clinical development efforts, particularly for DM1 clinical trials, with remaining funds directed towards general corporate purposes [5].